

NEKTAR THERAPEUTICS  
Form 8-K  
January 23, 2003

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

**Current Report Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 15, 2003**

### **Nektar Therapeutics**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-23556**

(Commission File Number)

**94-3134940**

(IRS Employer Identification No.)

**150 Industrial Road, San Carlos, CA**

(Address of principal executive offices)

**94070**

(Zip Code)

Registrant's telephone number, including area code: **(650) 631-3100**

**Inhale Therapeutic Systems, Inc.**

(Former name or former address, if changed since last report.)

---

---

**Item 5. Other Events and Regulation FD Disclosure**

Effective January 15, 2003 at 12:01 a.m., the registrant changed its corporate name from Inhale Therapeutic Systems, Inc. to Nektar Therapeutics (the *Company*). Further, effective January 15, 2003, the Company changed its trading symbol on the Nasdaq Stock Market from INHL to NKTR.

The Company effected the corporate name change by filing a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware, pursuant to which a wholly owned subsidiary of the Company merged with and into the Company (the *Merger*). A copy of the Certificate of Ownership and Merger is attached hereto as Exhibit 3.1. The Company is the surviving corporation in the Merger.

As a result of the corporate name change, the Company revised its specimen common stock certificate. A copy of which is attached hereto as Exhibit 4.1.

**Item 7. Financial Statements and Exhibits**

(a) **Financial Statements of business acquired.**

Not applicable.

(b) **Pro forma financial information.**

Not applicable.

(c) **Exhibits.**

<b>Exhibit Number</b>	<b>Description</b>
3.1	Certificate of Ownership and Merger of registrant
4.1	Specimen common stock certificate of registrant



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INHALE THERAPEUTIC SYSTEMS, INC.**

Dated: January 23, 2003

By: /s/ Brigid A. Makes

Brigid A. Makes  
Chief Financial Officer, Vice President of Finance  
and Administration and Assistant Secretary  
(Principal Financial and Accounting Officer)